Crispr Therapeutics Editas Medicine: Better Buy in 2026?
Two top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
We compare the 2024 outlook for index funds and target date funds to help you choose the right retirement path.
23,982 articlesTwo top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
After a market pullback, the opportunity to own high-quality companies can appear. This guide highlights two dependab...
Rookie landlord decisions often come down to two questions: should I pay off my property more or buy more? And how ca...
Savers are rethinking cash holdings as rates rise. Here are three higher-yield alternatives traditional savings that ...
As markets enter the quieter summer season, space-themed investing offers a targeted way to capture innovation. This ...
A high-stakes exit valued at about $5.5 million and a difficult first quarter have investors re-evaluating risk in bi...
A remote Canadian worksite faced a rare black bear incident that claimed a contractor's life. This article uses the t...
Trump declares the U.S.-Iran peace deal complete, sending stock futures higher and oil prices fluctuating. Yet analys...
Buffett's latest caution mirrors his Dot-Com-era warnings. In a market buzzing with hype, where does prudence fit in?...
President Trump signals possible limited military action against Iran as nuclear talks proceed, a move that could res...
Russia’s accusation that the United States carried out a ‘pre-planned’ strike against Iran jolts global markets as oi...
Markets wobbled as President Trump labeled Iran’s ceasefire reply 'TOTALLY UNACCEPTABLE,' fueling a risk-off mood ami...